MedTrace Logo

Efficacy and Safety of Litramine in 1 Year Weight Loss Study

NCT03227276 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 166

Last updated 2020-02-28

No results posted yet for this study

Summary

To evaluate the efficacy of Litramine in reducing body weight in the context of an energy-restricted diet in overweight and moderately obese subjects

Conditions

  • Obesity; Excess Calories
  • Overweight and Obesity
  • Weight Loss

Interventions

DIETARY_SUPPLEMENT

Litramine

2 tablets to be taken 3 times a day after meals

DIETARY_SUPPLEMENT

Placebo tablet

2 tablets to be taken 3 times a day after meals

Sponsors & Collaborators

  • InQpharm Group

    lead INDUSTRY

Principal Investigators

  • Udo Bongartz, MD · Analyze & Realize

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-14
Primary Completion
2020-02-19
Completion
2020-02-19

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03227276 on ClinicalTrials.gov